



GOV. MSG. NO. 1296

EXECUTIVE CHAMBERS
HONOLULU

DAVID Y. IGE
GOVERNOR

July 1, 2015

The Honorable Ronald D. Kouchi,
President
and Members of the Senate
Twenty-Eighth State Legislature
State Capitol, Room 409
Honolulu, Hawai'i 96813

The Honorable Joseph M. Souki,
Speaker and Members of the
House of Representatives
Twenty-Eighth State Legislature
State Capitol, Room 431
Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Souki, and Members of the Legislature:

This is to inform you that on July 1, 2015, the following bill was signed into law:

SB1131 SD2 HD2 CD1

RELATING TO THE UNIFORM CONTROLLED
SUBSTANCES ACT
ACT 195 (15)

Sincerely,

A handwritten signature in black ink that reads "David Y. Ige".

DAVID Y. IGE
Governor, State of Hawai'i

RECEIVED
SENATE
OFFICE OF THE PRESIDENT

RECEIVED
THE SENATE
CLERK'S OFFICE
STATE OF HAWAII

'15 JUL -1 P3:12

'15 JUL -1 P4:18

John A. Burns

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended by amending subsections (f) and (g) to read as follows:

3 "(f) Stimulants. Unless specifically excepted or unless
4 listed in another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances having a stimulant effect on the central nervous
7 system, including its salts, isomers, and salts of isomers:

- 8 (1) Aminorex;
- 9 (2) Cathinone;
- 10 (3) Fenethylamine;
- 11 (4) Methcathinone;
- 12 (5) N-ethylamphetamine;
- 13 (6) 4-methylaminorex;
- 14 (7) N,N-dimethylamphetamine; and
- 15 (8) Substituted cathinones, any compound, except bupropion
16 or compounds listed under a different schedule,
17 structurally derived from 2-aminopropan-1-ol by
18 substitution at the 1-position with either phenyl,



1 naphthyl, or thiophene ring systems, whether or not
2 the compound is further modified in any of the
3 following ways:

- 4 (A) By substitution in the ring system to any extent
5 with alkyl, alkylenedioxy, alkoxy, haloalkyl,
6 hydroxyl, or halide substituents, whether or not
7 further substituted in the ring system by one or
8 more other univalent substituents;
- 9 (B) By substitution at the 3-position with an acyclic
10 alkyl substituent; or
- 11 (C) By substitution at the 2-amino nitrogen atom with
12 alkyl, dialkyl, benzyl, or methoxybenzyl groups,
13 or by inclusion of the 2-amino nitrogen atom in a
14 cyclic structure.

15 Some other trade names: Mephedrone (2-methylamino-1-
16 p-tolylpropan-1-one), also known as 4-
17 methylmethcathinone (4-MMC), methylephedrone or MMCAT;
18 Methylenedioxyprovalerone (MDPV, MDPK); [and]
19 methylone or 3,4-methylenedioxymethcathinone[-]; and
20 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-
21 one, monohydrochloride, also known as Ethylone, bk-



1 MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-
2 ethylcathinone; bk-Methylenedioxyethylamphetamine.

3 (g) Any of the following cannabinoids, their salts,
4 isomers, and salts of isomers, unless specifically excepted,
5 whenever the existence of these salts, isomers, and salts of
6 isomers is possible within the specific chemical designation:

7 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
8 naturally contained in a plant of the genus Cannabis
9 (cannabis plant), as well as synthetic equivalents of
10 the substances contained in the plant, or in the
11 resinous extractives of Cannabis, sp. or synthetic
12 substances, derivatives, and their isomers with
13 similar chemical structure and pharmacological
14 activity to those substances contained in the plant,
15 such as the following: Delta 1 cis or trans
16 tetrahydrocannabinol, and their optical isomers; Delta
17 6 cis or trans tetrahydrocannabinol, and their optical
18 isomers; and Delta 3,4 cis or trans-
19 tetrahydrocannabinol, and its optical isomers (since
20 nomenclature of these substances is not
21 internationally standardized, compounds of these



- 1 structures, regardless of numerical designation of
2 atomic positions, are covered);
- 3 (2) Naphthoylindoles; meaning any compound containing a
4 3-(1-naphthoyl) indole structure with substitution at
5 the nitrogen atom of the indole ring by a alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8 ethyl group, whether or not further substituted in the
9 indole ring to any extent and whether or not
10 substituted in the naphthyl ring to any extent;
- 11 (3) Naphthylmethylinindoles; meaning any compound containing
12 a 1H-indol-3-yl-(1-naphthyl) methane structure with
13 substitution at the nitrogen atom of the indole ring
14 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
16 2-(4-morpholinyl) ethyl group whether or not further
17 substituted in the indole ring to any extent and
18 whether or not substituted in the naphthyl ring to any
19 extent;
- 20 (4) Naphthoylpyrroles; meaning any compound containing a
21 3-(1-naphthoyl) pyrrole structure with substitution at



1 the nitrogen atom of the pyrrole ring by a alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
4 ethyl group whether or not further substituted in the
5 pyrrole ring to any extent, whether or not substituted
6 in the naphthyl ring to any extent;

7 (5) Naphthylmethylenes; meaning any compound containing
8 a naphthylideneindene structure with substitution at
9 the 3-position of the indene ring by a alkyl,
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
12 ethyl group whether or not further substituted in the
13 indene ring to any extent, whether or not substituted
14 in the naphthyl ring to any extent;

15 (6) Phenylacetylindoles; meaning any compound containing a
16 3-phenylacetylindole structure with substitution at
17 the nitrogen atom of the indole ring by a alkyl,
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
20 ethyl group whether or not further substituted in the



- 1 indole ring to any extent, whether or not substituted
2 in the phenyl ring to any extent;
- 3 (7) Cyclohexylphenols; meaning any compound containing a
4 2-(3-hydroxycyclohexyl) phenol structure with
5 substitution at the 5-position of the phenolic ring by
6 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
7 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
8 2-(4-morpholinyl) ethyl group whether or not
9 substituted in the cyclohexyl ring to any extent;
- 10 (8) Benzoylindoles; meaning any compound containing a
11 3-(benzoyl) indole structure with substitution at the
12 nitrogen atom of the indole ring by a alkyl,
13 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
15 ethyl group whether or not further substituted in the
16 indole ring to any extent and whether or not
17 substituted in the phenyl ring to any extent;
- 18 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
19 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
20 [~~naphthalenylmethanone~~] naphthalenylmethanone (another
21 trade name is WIN 55,212-2);



- 1 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
2 methyloctan-2-yl)-6a,7,10,10a-
3 tetrahydrobenzo[c]chromen-1-ol (other trade names are:
4 HU-210 and HU-211);
- 5 (11) Tetramethylcyclopropanoylindoles; meaning any compound
6 containing a 3-tetramethylcyclopropanoylindole
7 structure with substitution at the nitrogen atom of
8 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
9 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
10 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
11 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
12 morpholinyl)methyl, or tetrahydropyranylmethyl group,
13 whether or not further substituted in the indole ring
14 to any extent and whether or not substituted in the
15 tetramethylcyclopropyl ring to any extent;
- 16 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
17 its optical, positional, and geometric isomers, salts,
18 and salts of isomers (Other names: APINACA, AKB48);
- 19 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
20 optical, positional, and geometric isomers, salts, and
21 salts of isomers (Other names: PB-22; QUPIC);



- 1 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
2 carboxylate, its optical, positional, and geometric
3 isomers, salts, and salts of isomers (Other names: 5-
4 fluoro-PB-22; 5F-PB-22);
- 5 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
6 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
7 positional, and geometric isomers, salts, and salts of
8 isomers (Other names: AB-FUBINACA); [~~and~~]
- 9 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
10 indazole-3-carboxamide, its optical, positional, and
11 geometric isomers, salts, and salts of isomers (Other
12 names: ADB-PINACA) [~~-~~];
- 13 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
14 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
15 optical, positional, and geometric isomers, salts, and
16 salts of isomers (Other names: AB-CHMINACA);
- 17 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
18 indazole-3-carboxamide, and geometric isomers, salts,
19 and salts of isomers (Other names: AB-PINACA);



- 1 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
2 yl)methanone, and geometric isomers, salts, and salts
3 of isomers (Other names: THJ-2201);
- 4 (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
5 valinate, and geometric isomers, salts, and salts of
6 isomers (other names: FUB-AMB);
- 7 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
8 carboxamido)-3-methylbutanoate, and geometric isomers,
9 salts, and salts of isomers (Other names: 5-fluoro-
10 AMB, 5-fluoro-AMP);
- 11 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
12 indazole-3-carboxamide, and geometric isomers, salts,
13 and salts of isomers (Other names: AKB48 N-(5-
14 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
15 analog, 5F-APINACA);
- 16 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
17 geometric isomers, salts, and salts of isomers (Other
18 names: STS-135, 5F-APICA; 5-fluoro-APICA); and
- 19 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
20 caboxylate, and geometric isomers, salts, and salts of
21 isomers (Other names: NM2201)."



1 SECTION 2. Section 329-18, Hawaii Revised Statutes, is
2 amended by amending subsection (e) to read as follows:

3 "(e) Narcotic drugs. Unless specifically excepted or
4 unless listed in another schedule, any material, compound,
5 mixture, or preparation containing any of the following narcotic
6 drugs, or their salts, or alkaloid, in limited quantities as set
7 forth below:

8 (1) Not more than 1.8 grams of codeine, or any of its
9 salts, per 100 milliliters or not more than 90
10 milligrams per dosage unit, with an equal or greater
11 quantity of an isoquinoline alkaloid of opium;

12 (2) Not more than 1.8 grams of codeine, or any of its
13 salts, per 100 milliliters or not more than 90
14 milligrams per dosage unit, with one or more active,
15 nonnarcotic ingredients in recognized therapeutic
16 amounts;

17 ~~[(3) Not more than 300 milligrams of dihydrocodeinone~~
18 ~~(Hydrocodone), or any of its salts, per 100~~
19 ~~milliliters or not more than 15 milligrams per dosage~~
20 ~~unit, with a fourfold or greater quantity of an~~
21 ~~isoquinoline alkaloid of opium provided that these~~



- 1 ~~narcotic drugs shall be monitored pursuant to section~~
2 ~~329-101,~~
- 3 ~~(4) Not more than 300 milligrams of dihydrocodeinone~~
4 ~~(Hydrocodone), or any of its salts per 100 milliliters~~
5 ~~or not more than 15 milligrams per dosage unit, with~~
6 ~~one or more active, nonnarcotic ingredients in~~
7 ~~recognized therapeutic amounts provided that these~~
8 ~~narcotic drugs shall be monitored pursuant to section~~
9 ~~329-101,~~
- 10 ~~(5)]~~ (3) Not more than 1.8 grams of dihydrocodeine, or any
11 of its salts, per 100 milliliters or not more than 90
12 milligrams per dosage unit, with one or more active,
13 nonnarcotic ingredients in recognized therapeutic
14 amounts;
- 15 ~~(6)]~~ (4) Not more than 300 milligrams of ethylmorphine, or
16 any of its salts, per 100 milliliters or not more than
17 15 milligrams per dosage unit, with one or more
18 ingredients in recognized therapeutic amounts;
- 19 ~~(7)]~~ (5) Not more than 500 milligrams of opium per 100
20 milliliters or per 100 grams, or not more than 25
21 milligrams per dosage unit, with one or more active

1 nonnarcotic ingredients in recognized therapeutic
2 amounts;

3 ~~[(+8)]~~ (6) Not more than 50 milligrams of morphine or any of
4 its salts, per 100 milliliters or per 100 grams with
5 one or more active, nonnarcotic ingredients in
6 recognized therapeutic amounts; and

7 ~~[(+9)]~~ (7) Buprenorphine."

8 SECTION 3. Section 329-20, Hawaii Revised Statutes, is
9 amended as follows:

10 1. By amending subsection (b) to read:

11 "(b) Depressants. Any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 substances, including its salts, isomers, esters, ethers, and
14 salts of isomers, whenever the existence of these isomers,
15 esters, ethers, and salts is possible within the specific
16 chemical designation, that has a degree of danger or probable
17 danger associated with a depressant effect on the central
18 nervous system:

- 19 (1) Alprazolam;
- 20 (2) Barbital;
- 21 (3) Bromazepam;



- 1 (4) Butorphanol;
- 2 (5) Camazepam;
- 3 (6) Carisoprodol;
- 4 (7) Chloral betaine;
- 5 (8) Chloral hydrate;
- 6 (9) Chlordiazepoxide;
- 7 (10) Clobazam;
- 8 (11) Clonazepam;
- 9 (12) Clorazepate;
- 10 (13) Clotiazepam;
- 11 (14) Cloxazolam;
- 12 (15) Delorazepam;
- 13 (16) Dichloralphenazone (Midrin);
- 14 (17) Diazepam;
- 15 (18) Estazolam;
- 16 (19) Ethchlorvynol;
- 17 (20) Ethinamate;
- 18 (21) Ethyl loflazepate;
- 19 (22) Fludiazepam;
- 20 (23) Flunitrazepam;
- 21 (24) Flurazepam;



- 1 (25) Fospropofol (Lusedra);
- 2 (26) Halazepam;
- 3 (27) Haloxazolam;
- 4 (28) Ketazolam;
- 5 (29) Loprazolam;
- 6 (30) Lorazepam;
- 7 (31) Lormetazepam;
- 8 (32) Mebutamate;
- 9 (33) Medazepam;
- 10 (34) Meprobamate;
- 11 (35) Methohexital;
- 12 (36) Methylphenobarbital (mephorbarbital);
- 13 (37) Midazolam;
- 14 (38) Nimetazepam;
- 15 (39) Nitrazepam;
- 16 (40) Nordiazepam;
- 17 (41) Oxazepam;
- 18 (42) Oxazolam;
- 19 (43) Paraldehyde;
- 20 (44) Petrichloral;
- 21 (45) Phenobarbital;



- 1 (46) Pinazepam;
- 2 (47) Prazepam;
- 3 (48) Quazepam;
- 4 (49) Suvorexant;
- 5 [~~49~~] (50) Temazepam;
- 6 [~~50~~] (51) Tetrazepam;
- 7 [~~51~~] (52) Triazolam;
- 8 [~~52~~] (53) Zaleplon;
- 9 [~~53~~] (54) Zolpidem; and
- 10 [~~54~~] (55) Zopiclone (Lunesta)."

11 2. By amending subsection (g) to read:

12 "(g) Narcotic drugs. . Unless specifically excepted or
13 unless listed in another schedule, any material, compound,
14 mixture, or preparation containing any of the following narcotic
15 drugs, or their salts calculated as the free anhydrous base or
16 alkaloid, in limited quantities as set forth below:

- 17 (1) Not more than one milligram of difenoxin and not less
18 than twenty-five micrograms of atropine sulfate per
19 dosage unit; [~~and~~]
- 20 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-
21 diphenyl-3-methyl-2-propionoxybutane) [~~-~~]; and




1 (3) 2-[(dimethylamino)methyl]-1-(3-
2 methoxyphenyl)cyclohexanol, its salts, optical and
3 geometric isomers and salts of these isomers
4 (including tramadol)."

5 SECTION 4. Statutory material to be repealed is bracketed
6 and stricken. New statutory material is underscored.

7 SECTION 5. This Act shall take effect upon its approval.

APPROVED this 1 day of JUL , 2015



GOVERNOR OF THE STATE OF HAWAII